UNICHEM LABORATORIES
|
UNICHEM LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 35.91 | 19.53 | -13.32 | -28.72 | 4.70 |
| CEPS(Rs) | 53.69 | 37.23 | 4.18 | -12.61 | 17.64 |
| DPS(Rs) | - | - | - | - | 4.00 |
| Book NAV/Share(Rs) | 385.16 | 347.37 | 345.91 | 344.18 | 370.39 |
| Tax Rate(%) | 13.52 | 11.04 | -10.36 | -14.67 | -50.49 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 8.36 | 12.55 | 4.87 | -3.39 | 5.73 |
| EBIT Margin(%) | 14.71 | 8.32 | -3.49 | -11.84 | 2.21 |
| Pre Tax Margin(%) | 13.28 | 7.32 | -4.76 | -13.13 | 1.73 |
| PAT Margin (%) | 11.48 | 6.51 | -5.25 | -15.06 | 2.60 |
| Cash Profit Margin (%) | 17.17 | 12.42 | 1.65 | -6.61 | 9.78 |
| Performance Ratios | |||||
| ROA(%) | 6.97 | 4.04 | -2.91 | -6.22 | 1.03 |
| ROE(%) | 9.81 | 5.64 | -3.86 | -8.04 | 1.28 |
| ROCE(%) | 10.68 | 6.34 | -2.31 | -5.60 | 1.00 |
| Asset Turnover(x) | 0.61 | 0.62 | 0.55 | 0.41 | 0.40 |
| Sales/Fixed Asset(x) | 1.10 | 1.08 | 0.97 | 0.86 | 0.99 |
| Working Capital/Sales(x) | 1.68 | 2.03 | 1.77 | 1.42 | 1.16 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.90 | 0.93 | 1.03 | 1.17 | 1.01 |
| Receivable days | 133.23 | 122.86 | 125.84 | 147.31 | 107.17 |
| Inventory Days | 162.76 | 149.13 | 139.19 | 166.52 | 163.63 |
| Payable days | 145.35 | 179.36 | 183.72 | 179.25 | 201.09 |
| Valuation Parameters | |||||
| PER(x) | 8.18 | 35.47 | - | - | 55.44 |
| PCE(x) | 5.47 | 18.61 | 116.97 | -22.92 | 14.76 |
| Price/Book(x) | 0.76 | 1.99 | 1.41 | 0.84 | 0.70 |
| Yield(%) | - | - | - | - | 1.54 |
| EV/Net Sales(x) | 1.02 | 2.46 | 1.96 | 1.60 | 1.61 |
| EV/Core EBITDA(x) | 9.07 | 17.29 | 29.54 | -304.97 | 17.03 |
| EV/EBIT(x) | 6.92 | 29.55 | -56.18 | -13.50 | 73.00 |
| EV/CE(x) | 0.70 | 1.80 | 1.32 | 0.79 | 0.62 |
| M Cap / Sales | 0.94 | 2.31 | 1.93 | 1.52 | 1.44 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 4.31 | 18.25 | 32.92 | 5.76 | 2.81 |
| Core EBITDA Growth(%) | -17.64 | 153.38 | 1,782.74 | -105.85 | -14.86 |
| EBIT Growth(%) | 84.47 | 381.89 | 60.83 | -666.54 | -50.70 |
| PAT Growth(%) | 83.86 | 246.67 | 53.64 | -711.67 | -4.63 |
| EPS Growth(%) | 83.86 | 246.67 | 53.63 | -711.66 | -3.68 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.17 | 0.18 | 0.09 | 0.12 | 0.13 |
| Current Ratio(x) | 2.48 | 2.05 | 2.36 | 2.48 | 2.98 |
| Quick Ratio(x) | 1.38 | 1.05 | 1.37 | 1.51 | 1.89 |
| Interest Cover(x) | 10.26 | 8.35 | -2.75 | -9.19 | 4.60 |
| Total Debt/Mcap(x) | 0.23 | 0.09 | 0.06 | 0.15 | 0.18 |
Compare Financial Ratios of peers of UNICHEM LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| UNICHEM LABORATORIES | ₹4,024.4 Cr | 23.4% | 60.1% | -20.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹452,982.0 Cr | 0.9% | 5.6% | 14.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,361.0 Cr | 1.2% | 3.7% | -1.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹164,737.0 Cr | 4.4% | 10.3% | 42.1% | Stock Analytics | |
| CIPLA | ₹115,655.0 Cr | -1.7% | 3.1% | -4.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,573.0 Cr | 0.2% | 5.7% | 6% | Stock Analytics | |
UNICHEM LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| UNICHEM LABORATORIES | 23.4% |
60.1% |
-20.1% |
| SENSEX | -0.5% |
3% |
-8.5% |
You may also like the below Video Courses
